Instil Bio, Inc.
NASDAQ:TILBiotechnology
Healthcare
$7.45 +0.13%
+$0.01 today
- Market cap
- $50.53M
- Beta
- 1.91
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$6.99
52W Low $5.67High $33.83
Volume 0.02M
Average 0.03M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$36.62M
FY 2025 · Annual
Investing Cash Flow
$25.48M
FY 2025 · Annual
-52.8% YoYFinancing Cash Flow
$7.29M
FY 2025 · Annual
+315.5% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (156.79M) | (223.18M) | (156.09M) | (74.14M) | (71.37M) |
| Depreciation & Amortization | 2.75M | 5.99M | 4.76M | 3.61M | 534K |
| Deferred Income Tax | 710K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 26.2M | 30.44M | 18.17M | 17.26M | 8.69M |
| Change in Working Capital | 4.36M | (9.57M) | (9.02M) | (12.61M) | (560K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | (3.4M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.86M | (1.81M) | (1.13M) | (556K) | 116K |
| Other Working Capital | 499K | (7.76M) | (7.89M) | (12.05M) | 2.72M |
| Other Non-Cash Items | 636K | 16.15M | 60.15M | 10.18M | 26.09M |
| Operating Cash Flow | (122.14M) | (180.16M) | (82.03M) | (55.7M) | (36.62M) |
| Capital Expenditures | (57.83M) | (84.59M) | (20.66M) | (10M) | 0 |
| Acquisitions (Net) | 0 | 1.17M | 0 | 0 | 432K |
| Purchases of Investments | (1.11B) | (666.22M) | (301.47M) | (135.6M) | (100.86M) |
| Sales of Investments | 691M | 865.35M | 361.7M | 198.71M | 135.9M |
| Other Investing Activities | 0 | (1.17M) | 1.56M | 866K | 0 |
| Investing Cash Flow | (474.4M) | 114.54M | 41.13M | 53.97M | 25.48M |
| Debt Repayment | 0 | 70.34M | 8.08M | 2.76M | 6.61M |
| Common Stock Issued | 339.02M | 1.55M | 0 | 0 | 853K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.69M | 0 | 0 | (1.01M) | (172K) |
| Financing Cash Flow | 393.16M | 71.89M | 8.08M | 1.76M | 7.29M |
| Effect of Forex Changes | (304K) | (637K) | (201K) | (94K) | 20K |
| Net Change in Cash | (203.67M) | 5.63M | (33.02M) | (61K) | (3.83M) |
| Free Cash Flow | (179.97M) | (264.75M) | (102.69M) | (65.7M) | (36.62M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$71.4M
+ D&A$534.0K
+ Stock-Based Comp$8.7M
+ Deferred Tax$0
- Working Capital-$560.0K
+ Other Non-Cash$26.1M
= Operating Cash Flow-$36.6M
- Capex$0
= Free Cash Flow-$36.6M
Analysis
FY2025 free cash flow is -$36.6M. FCF conversion is 51.3% of net income. Operating cash flow was -$36.6M, with capex of $0. The largest bridge item is Other Non-Cash at $26.1M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | |
| 8-K | Current report | Aug 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 12, 2026 |
Does TIL generate free cash flow?
Instil Bio, Inc. (TIL) generated -$36.62M of free cash flow in fiscal 2025.
How much operating cash flow does TIL produce?
Operating cash flow was -$36.62M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.